HoldsUp

Jed Fahey

Dr. Jed Fahey is a researcher specializing in chemoprotection and phytochemical science. His published work focuses primarily on the bioavailability, mechanisms, and therapeutic potential of sulforaphane, glucoraphanin, and other isothiocyanates. His clinical studies evaluate the effects of these plant-derived compounds across various conditions, including autism spectrum disorder, schizophrenia, prediabetes, skin disorders, and cancer.

45 claims checked on air: 3 context 1 contradicted 39 supported 2 unverified 1 flagged

What they said on air - context

12 citing their own research

0:07:00needs contextmoderatetheir own paperQ&A with Dr. Jed Fahey on Sulforaphane, Moringa and Chemopro

Clinical studies on sulforaphane typically target a daily dosage of between 50 and 100 micromoles.

"all the clinical studies seem to be pointing towards a dose of something between about 50 and 100 micromoles of sulforaphane a day." (said at 0:07:00)

Human clinical trials testing sulforaphane and its precursor glucoraphanin commonly employ doses in the range of 50 to 200 micromoles (µmol) per day, making the 50–100 µmol/day target an accurate reflection of many standard research protocols. For example, Phase I pharmacokinetic and safety trials administered oral doses such as 25 µmol every 8 hours (totaling 75 µmol/day) of isothiocyanates or 100 µmol per dose of glucosinolates, and other intervention trials have used doses ranging from small microgram amounts up to 200 µmol/day. However, clinical studies vary widely depending on whether free sulforaphane, glucoraphanin-rich broccoli sprout extracts, or whole food preparations are used.

0:38:19needs contextlowQ&A with Dr. Jed Fahey on Sulforaphane, Moringa and Chemopro

Glutathione production declines naturally with age starting as early as in one's 20s.

"It declines naturally with age, and in fact, starting as early as in your 20s." (said at 0:38:19)

Glutathione levels and synthesis rates do decline with age in humans. Tracer and metabolic studies demonstrate that older adults have significantly lower red blood cell glutathione concentrations and substantially reduced fractional and absolute glutathione synthesis rates compared to healthy young adults in their 20s and 30s. However, stating that synthesis begins to decline specifically in one's 20s reflects a common extrapolation from cross-sectional studies that compare young adult baselines (typically individuals in their 20s) to older cohorts, rather than continuous longitudinal proof of an active drop within the 20s.

1:41:03needs contextmoderatetheir own paperQ&A with Dr. Jed Fahey on Sulforaphane, Moringa and Chemopro

In a 2014 autism trial evaluating daily sulforaphane consumption, the only instances where thyroid function was flagged occurred in participants in the placebo group.

"So in one of our studies, the autism study that we published in 2014, there were questions from the IRB—which is made up of, among other things, physicians—about the potential for thyroid issues and were we going to monitor thyroid chemistry. And we did ... And as I recall, there were a couple of times when thyroid function was flagged, and they wound up being in placebos, those that are getting placebo." (said at 1:41:03)

In the 2014 randomized, double-blind, placebo-controlled trial evaluating sulforaphane in young men with autism spectrum disorder (Singh et al., 2014), 29 participants received daily sulforaphane (50–150 µmol) and 15 received placebo for 18 weeks. While the trial verified the low toxicity and clinical safety profile of sulforaphane without treatment-related adverse events, specific internal laboratory monitoring incident reports (such as isolated borderline thyroid test flags occurring in placebo recipients during clinical safety monitoring) are detailed in trial monitoring records rather than the primary abstract.

Fact-checked episodes

Publications